Table 1 Summarizing significant changes in time-dependent regulation of MAPK/Erk1/2 and Akt/GSK-3 pathways, in nuclei and cytosol from PFC/FC and HPC of vehicle (VHE) or agomelatine (AGO) treated rats, sacrificed 1 h or 16 h after last injection
From: Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine
Protein (figure number) | Brain area | Subcellular fraction | Variable | F statistic | 2 Way ANOVA P value | Significant Bonferroni post-hoc tests |
|---|---|---|---|---|---|---|
pERK 1 (Figure 1F) | PFC/FC | nucleus | treatment | F(1,26) = 1.62 | P = 0.2147 | AGO 16 h vs. |
time | F(1,26) = 12.88 | P < 0.01 | AGO 1 h p < 0.05 | |||
interaction | F(1,26) = 0.46 | P = 0.5042 | ||||
pERK 2 (Figure 1H) | PFC/FC | nucleus | treatment | F(1,26) = 4.49 | P < 0.05 | AGO 16 h vs. |
time | F(1,26) = 18.55 | P < 0.001 | AGO 1 h p < 0.01 | |||
interaction | F(1,26) = 0.22 | P = 0.6401 | ||||
pERK 1 (Figure 2F) | HPC | nucleus | treatment | F(1,26) = 2.45 | P = 0.1300 | VEH 16 h vs. |
time | F(1,26) = 28.50 | P < 0.0001 | VEH 1 h p < 0.01 | |||
interaction | F(1,26) = 0.13 | P = 0.7201 | AGO 16 h vs. | |||
AGO 1 h p < 0.001 | ||||||
pERK 2 (Figure 2H) | HPC | nucleus | treatment | F(1,26) = 3.24 | P = 0.0833 | VEH 16 h vs. |
time | F(1,26) = 31.72 | P < 0.0001 | VEH 1 h p < 0.01 | |||
interaction | F(1,26) = 0.11 | P = 0.7476 | AGO 16 h vs. | |||
AGO 1 h p < 0.001 | ||||||
pThr308 Akt (Figure 3B) | PFC/FC | nucleus | treatment | F(1,28) = 0.61 | P = 0.4429 | VEH 16 h vs. |
time | F(1,28) = 17.43 | P < 0.001 | VEH 1 h p < 0.001 | |||
interaction | F(1,28) = 2.00 | P = 0.1685 | ||||
pSer473 Akt (Figure 3C) | PFC/FC | nucleus | treatment | F(1,28) = 5.96 | P < 0.05 | VEH 16 h vs. |
time | F(1,28) = 21.54 | P < 0.0001 | VEH 1 h p < 0.01 | |||
interaction | F(1,28) = 0.00 | P = 0.9631 | AGO 16 h vs. | |||
AGO 1 h p < 0.01 | ||||||
pSer9 GSK-3β (Figure 3F) | PFC/FC | nucleus | treatment | F(1,28) = 0.00 | P = 0.9779 | VEH 16 h vs. |
time | F(1,28) = 22.06 | P < 0.0001 | VEH 1 h p < 0.01 | |||
interaction | F(1,28) = 0.09 | P = 0.7695 | AGO 16 h vs. | |||
AGO 1 h p < 0.01 | ||||||
pSer473 Akt (Figure 4C) | PFC/FC | cytosol | treatment | F(1,28) = 4.15 | P = 0.0512 | VEH 16 h vs. |
time | F(1,28) = 8.33 | P < 0.01 | VEH 1 h p < 0.05 | |||
interaction | F(1,28) = 0.22 | P = 0.6429 | ||||
pTyr216 GSK-3 β (Figure 4E) | PFC/FC | cytosol | treatment | F(1,28) = 2.87 | P = 0.1016 | AGO 16 h vs. |
time | F(1,28) = 12.54 | P < 0.05 | AGO 1 h p < 0.05 | |||
interaction | F(1,28) = 0.25 | P = 0.6183 | ||||
pThr308 Akt (Figure 5B) | HPC | nucleus | treatment | F(1,28) = 0.46 | P = 0.5017 | VEH 16 h vs. |
time | F(1,28) = 21.92 | P < 0.0001 | VEH 1 h p < 0.01 | |||
interaction | F(1,28) = 0.34 | P = 0.5669 | AGO 16 h vs. | |||
AGO 1 h p < 0.05 | ||||||
pSer473 Akt (Figure 5C) | HPC | nucleus | treatment | F(1,28) = 0.86 | P = 0.3626 | AGO 16 h vs. |
time | F(1,28) = 14.89 | P < 0.001 | AGO 1 h p < 0.01 | |||
interaction | F(1,28) = 0.29 | P = 0.5928 | ||||
Akt tot (Figure 6A) | HPC | cytosol | treatment | F(1,28) = 0.30 | P = 0.5863 | - |
time | F(1,28) = 6.19 | P < 0.05 | ||||
interaction | F(1,28) = 0.18 | P = 0.6777 | ||||
pThr308 Akt (Figure 6B) | HPC | cytosol | treatment | F(1,28) = 1.34 | P = 0.2567 | VEH 16 h vs. |
time | F(1,28) = 9.61 | P < 0.01 | VEH 1 h p < 0.05 | |||
interaction | F(1,28) = 0.22 | P = 0.6447 | ||||
pSer473 Akt (Figure 6C) | HPC | cytosol | treatment | F(1,28) = 0.52 | P = 0.4788 | AGO 16 h vs. |
time | F(1,28) = 8.33 | P < 0.01 | AGO 1 h p < 0.01 | |||
interaction | F(1,28) = 4.75 | P < 0.05 |